Adrenal Pathophysiology: Lessons from the Carney Complex

Lionel Groussin  Laure Cazabat  Fernande René-Corail  Eric Jullian  Jérôme Bertherat

INSERM U 567, CNRS UMR 8104, Université René-Descartes Paris V, Institut Cochin, Paris, France

Key Words
Carney complex · Primary pigmented nodular adrenocortical disease · Cushing’s syndrome · Cyclic AMP · PRKAR1A gene

Abstract
The Carney complex (CNC) is a dominantly inherited syndrome responsible mainly for spotty skin pigmentation (lentiginosis), endocrine overactivity, and cardiac myxomas. Adrenocorticotrophic hormone independent Cushing’s syndrome due to primary pigmented nodular adrenocortical disease (PPNAD) is a main characteristic of CNC. PPNAD is a very rare cause of Cushing’s syndrome due to a primary bilateral adrenal defect that can be also observed in some patients without other CNC manifestations nor familial history. One of the putative CNC genes, located on 17q22-24, has been identified as the regulatory subunit R1A of protein kinase A (PRKAR1A). Heterozygous inactivating mutations of PRKAR1A have been reported initially in about 45% of the CNC index cases and could be found in about 80% of the CNC families presenting mainly with Cushing’s syndrome. PRKAR1A is a key component of the cyclic AMP signaling pathway that has been implicated in endocrine tumorigenesis and could, at least partly, function as a tumor suppressor gene. Interestingly, patients with isolated PPNAD and no familial history of CNC can also present a germline de novo mutation of PRKAR1A. Somatic mutations of PRKAR1A have been found in PPNAD as a mechanism of inactivation of the wild-type allele, in a patient already presenting a germline mutation, and in a subset of sporadic secreting adrenocortical adenomas with clinical, hormonal, and pathological features quite similar to PPNAD. This review will summarize the recent findings on CNC from the perspective of the pathophysiology of adrenal Cushing’s syndrome and PPNAD.

Introduction

The Carney complex (CNC; MIM 160980) was first described in 1985 by J. Aidan Carney and coworkers [1] at the Mayo Clinic as the complex of myxomas, spotty pigmentation, and endocrine overactivity. The identification of this rare syndrome came from the study of 4 patients with an unusual cause of Cushing’s syndrome published 1 year earlier as ‘primary pigmented nodular adrenocortical disease’ (PPNAD) [2]. By the analysis of the literature on similar cases of this rare cause of Cushing’s syndrome, the association with cardiac myxomas in the same family led to the speculation of a connection between these two rare disorders. The first description of CNC included 40 patients [1], among them 10 familial cases, leading to the hypothesis of a genetic origin, at least in a subset of patients. PPNAD is a rare cause of adrenocorticotropic hormone (ACTH) independent Cushing’s syndrome, occurring mainly in children and young adults. It could be diagnosed in no more than 1% of the patients...
with Cushing’s syndrome. The name was given after the macroscopic appearance of the adrenals that is characteristic with small pigmented micronodules observed in the cortex (fig. 1). The disease is usually bilateral with primary involvement of both adrenals.

One of the first case reports of Cushing’s syndrome due to PPNAD might have been published more than 50 years ago [see 3]. However, it was first reported as a specific entity in the late 60s [4]. Meador et al. [4] described a 14-year-old patient with dexamethasone-unsuppressible 17-hydroxycorticosteroid levels and undetectable plasma ACTH levels, even after adrenalectomy. The term ‘primary adrenocortical nodular dysplasia’ was used to describe the adrenal pathology with numerous black nodules <2 mm in diameter ‘resembling metastatic melanoma’. Several cases of Cushing’s syndrome with micronodules in the adrenal cortex were reported by others during the same period [5, 6]. Severe osteopenia in 2 young adults (19 and 23 years old) with Cushing’s syndrome due to micronodular adrenal disease was reported shortly after by Ruder et al. [7]. The detailed and current description of PPNAD was established with the description of the CNC [1–3]. Analysis of families with CNC suggested that this disease can be part of a dominantly inherited syndrome. This hypothesis was initially investigated by linkage analysis by Stratakis et al. [8], leading to the identification of at least two loci. The identification of one of the CNC genes (CNC1: PRKAR1A) proved this concept and gives new insight into the pathophysiology of PPNAD and adrenocortical tumors [9, 10]. PPNAD can typically be seen in patients with CNC, but it is also definitely diagnosed in some patients without other CNC manifestations or familial history. The recent progress in the genetics of CNC raised the question of a unique or multiple pathophysiology and genetics of PPNAD and whether it might be a unique disease or whether it could be observed as various subcategories of diseases, as discussed later in this review.

Clinical, Hormonal, and Imaging Investigations of PPNAD

Main Clinical Characteristics of PPNAD

Cushing’s syndrome due to PPNAD is observed in children and young adults. The peak age seems to be during the 2nd decade [3]. It is rare but may occur before the age of 4 years, and it is rarely diagnosed after the age of 40 years, even by systematic screening of patients with known CNC. The diagnosis of Cushing’s syndrome in PPNAD is often difficult because hypercortisolism can develop progressively over years. By contrast, in some patients rapid intense bursts of cortisol excess can be observed that might spontaneously regress. One of the first cases of PPNAD observed at the Mayo Clinic, in dizygotic twins just before World War II, had undergone spontaneous remission [3]. In some cases of PPNAD cyclic hypercortisolism has been documented [11–13]. The variations of the hypercortisolism observed in these patients with cyclic Cushing’s syndrome and low ACTH plasma levels, without obvious tumor on adrenal computed tomography scan, can lead to the suspicion of exogenous glucocorticoid administration by proxy in a child. Cushing’s syndrome due to PPNAD occurring during pregnancy has also been observed [14]. An in vitro stimulation of cortisol secretion by estradiol in a dose-dependent manner was reported after culture of PPNAD tissue from a patient with Cushing’s syndrome that was present during pregnancy and during oral contraceptive use [14]. PPNAD can now also be diagnosed by systematic screening of patients with CNC, investigated for other clinical manifestations of the complex, or by familial screening. The mean time between the first symptoms and the diagnosis was about 4 years in historical series [3]. Despite the unusual time course of Cushing’s syndrome that can be observed in some patients with PPNAD, clinical signs are quite similar to the observations made in patients presenting with other causes of hypercortisolism [3, 12, 15]. Central obesity and weight gain are the

Fig. 1. PPNAD: macroscopic appearance of the adrenal gland. The cut surfaces show multiple pigmented micronodules. The periadrenal fat is also visible around the adrenal capsule.
Hormonal Investigations in PPNAD

The urinary cortisol concentration is increased in most patients at the time of diagnosis of PPNAD, but its level can be highly variable [11, 12]. The circadian rhythm of cortisol is usually completely abolished. As for other causes of ACTH-independent Cushing’s syndrome, the plasma levels of ACTH are suppressed in patients with PPNAD. A classical biological feature of PPNAD is the discrepancy between a low plasma ACTH level and salivary or plasma cortisol concentrations remaining in the normal range or above. There is no stimulation of cortisol or ACTH after corticotropin-releasing hormone stimulation. In the same line, dexamethasone fails to suppress cortisol, even during high-dose administration. Interestingly, a paradoxical rise in the urinary cortisol level can be observed after dexamethasone treatment, particularly under high-dose administration (8 mg/day) [11]. This could be helpful in the diagnosis of PPNAD, especially in patients with normal basal urinary cortisol levels [16]. An increase of urinary cortisol of at least 100% seems quite specific for PPNAD. This stimulatory effect of a glucocorticoid can be observed during primary culture of PPNAD tissues in vitro. Interestingly, this in vitro effect of dexamethasone increases with a longer exposure, suggesting a positive autostimulating feedback loop of glucocorticoids in PPNAD. An increased glucocorticoid receptor expression has been observed in pigmented nodules of PPNAD patients and could take part in this dysregulation [16]. By immunohistochemistry, a high level of glucocorticoid receptor expression can be observed in the cytoplasm of cells located in the nodules. We have also made the same observation for the progesterone receptor [Raffin-Sanson and Bertherat, unpubl.]. Therefore, alterations of the cortisol secretion by various steroids could be a general phenomenon in PPNAD. This observation could be related to the finding discussed above of Cushing’s syndrome worsening during pregnancy in PPNAD and may be, in some cases, apparent transient hypercortisolism of pregnancy.

Imaging of PPNAD

At pathological investigation, adrenal glands from patients with PPNAD are usually normal in size and weigh between 4 and 17 g [3]. In keeping with these findings, the adrenals can appear normal on computed tomography scanning in 1 out of 3 patients. In the other patients, micronodules can be visible and, more rarely, macronodules (>1 cm in diameter) (fig. 2) in one or both glands [12]. Iodocholesterol scintigraphy, when performed, usually
shows a bilateral uptake despite ACTH suppression by endogenous hypercortisolism.

**Therapy of PPNAD**

Treatment of Cushing’s syndrome due to PPNAD is most often bilateral adrenalectomy. Some rare cases have been treated by mitotane, ketoconazole, or unilateral adrenalectomy. In the rare patients in whom overt Cushing’s syndrome did not recur after unilateral adrenalectomy, alterations of the dynamics of cortisol secretion could be observed on long-term follow-up, demonstrating that despite apparent cure the disease is indeed bilateral [17]. This observation could be related to the finding of an abnormal adrenocortical function observed in relatives of patients with CNC and no obvious Cushing’s syndrome. Therefore, the spectrum of cortisol dysregulation in PPNAD might be much broader than suggested when searching only for evident clinical signs of hypercortisolism. Similarly, PPNAD can be found at autopsy in CNC patients in whom no diagnosis of hypercortisolism has been made [3].

**Carney Complex**

CNC is an autosomal dominantly inherited multiple neoplasia syndrome. Along with PPNAD, among the tumors observed in CNC patients are growth hormone secreting pituitary adenomas (acromegaly), thyroid adenomas or carcinomas, testicular tumors (large-cell calcifying Sertoli cell tumors), ovarian cysts, melanocytic schwannomas, and breast ductal adenomas (table 1). A cardiac myxoma is also an important manifestation of CNC and could explain the high rate (10%) of sudden deaths reported in CNC families [8], underlying the importance of its early diagnosis. An ACTH-independent Cushing syndrome due to PPNAD is observed in 25–30% of the patients with CNC.

**Genetics of CNC**

CNC seems to be a genetically heterogeneous disease, and linkage analysis has shown that at least two loci are involved: 2p16 and 17q22-24. The CNC1 gene located on the 17q22-24 locus has been identified as the regulatory subunit R1A of protein kinase A (PRKAR1A) [9, 10]. PRKAR1A is a key component of the cAMP signaling pathway that has been implicated in endocrine tumorigenesis (fig. 3, 4). Heterozygous inactivating mutations of PRKAR1A have been reported in about 45% of the CNC families [18]. In CNC patients with Cushing’s syndrome, the frequency of PRKAR1A mutations is about 80%, suggesting that families with PPNAD are more likely to be associated with a 17q22-24 defect [19]. Interestingly, patients with isolated PPNAD and no familial history of CNC can also present a germline de novo mutation of PRKAR1A [12]. In the tumors of CNC patients, loss of heterozygosity (LOH) at 17q22-24 can be observed, suggesting that PRKAR1A is a tumor suppressor gene. Somatic mutation of PRKAR1A can occur in PPNAD as a mechanism of inactivation of the wild-type allele in a patient already presenting a germline mutation [12]. However, inactivation of the remaining wild-type allele by genetic alteration seems not a constant step in PPNAD and CNC tumor development [19].

**Table 1. Main features of CNC**

<table>
<thead>
<tr>
<th>Manifestation</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPNAD</td>
<td>25–45%</td>
</tr>
<tr>
<td>Cardiac myxoma</td>
<td>30–72%</td>
</tr>
<tr>
<td>Skin myxoma</td>
<td>63%</td>
</tr>
<tr>
<td>Lentiginosis</td>
<td>62%</td>
</tr>
<tr>
<td>Breast ductal adenoma</td>
<td>25%</td>
</tr>
<tr>
<td>Testicular tumors (LCCSCT = large-cell calcifying Sertoli cell tumor)</td>
<td>56%</td>
</tr>
<tr>
<td>Ovarian cyst</td>
<td>67%</td>
</tr>
<tr>
<td>Acromegaly</td>
<td>10%</td>
</tr>
<tr>
<td>Thyroid tumor</td>
<td>10%</td>
</tr>
<tr>
<td>Melanotic schwannoma</td>
<td>18%</td>
</tr>
<tr>
<td>Osteochondromyxoma</td>
<td>10%</td>
</tr>
</tbody>
</table>

Frequencies are given according to Carney et al. [1], Carney and Young [3], Stratakis et al. [8], and Kirschner et al. [18] and our personal observations.

a Manifestations of the disease that can be commonly observed in children younger than 10 years.

In PPNAD, it could also be that a general polyclonal expansion might be stimulated by haploinsufficiency due to the first germline defect; a second genetic hit leading to inactivation of the remaining wild-type allele might partially be correct for PRKAR1A. In PPNAD, it could also be that a general polyclonal expansion might be stimulated by haploinsufficiency due to the first germline defect; a second genetic hit leading to inactivation of the remaining wild-type allele might further stimulate tumorigenesis and the development of
adrenocortical nodules. In keeping with this hypothesis the somatic mutation observed in PPNAD in a patient already presenting a germline mutation was found only in a macronodule of 2.5 cm, a diameter unusually high for PPNAD nodules.

**Fig. 3.** The cAMP signaling pathway from the cell surface to the nucleus: The extracellular ligand (red circle) binds to its specific seven-domain transmembrane receptors (shown in red), leading to activation of a heterotrimeric (α, β and γ subunits) Gs protein (shown in yellow). Activation of the Gs protein leads to dissociation of its alpha subunit (αs) from the β, γ complex, stimulating adenylyl cyclase activity (AC, shown in green) and, therefore, cAMP production. After binding of cAMP, the PKA (shown in blue) is activated. The free catalytic subunit (C) then enters the nucleus and phosphorylates CREB at serine 133, leading to transactivation.

**Fig. 4.** cAMP-dependent PKA and its regulatory subunit R1A (PRKAR1A). A Schematic modular structure of PRKAR1A with the dimerization domain and the catalytic subunit binding domains on the amino-terminal part and two cAMP-binding sites on the carboxy-terminal part of the protein. B Mechanisms of activation of the PKA heterotetramer after cAMP stimulation. Binding of cAMP to the regulatory subunits leads to dissociation and hence activation of the catalytic subunits (C, shown in red).
in secretory adrenal adenomas. The adrenal adenomas harboring somatic PRKAR1A mutations present with clinical, hormonal, and pathological features quite similar to PPNAD [21]. These latter adenomas are small tumors responsible for Cushing’s syndrome and present a paradoxical rise of cortisol after dexamethasone treatment. Allelic losses (LOH) at the PRKAR1A locus (17q22-24) have also been observed in sporadic adrenocortical tumors. In adrenocortical adenomas these LOH seem quite restricted to the PRKAR1A locus, suggesting that this tumor suppressor gene might be involved. By contrast, in adrenocortical cancers LOH seems to affect a large part of 17q, and PRKAR1A alteration might play a minor (or no) role in the growth of these tumors.

Unsolved Questions in the Genetics of CNC and PPNAD

The putative CNC2 gene located at the 2p16 locus remains to be determined [8, 18]. However, somatic alterations of the 2p16 region have been reported in CNC tumors, even in patients with a mutation of the CNC1 gene (i.e., PRKAR1A located on 17q22-24). These alterations are usually gene amplifications, suggesting a potential oncogene at 2p16 [22]. In sporadic adrenocortical tumors, 2p16 amplification has been also reported [22, 23]. Considering the genetics of isolated PPNAD, it should be mentioned that a subgroup of very young pediatric patients might be different from older patients related to CNC. In these patients, the classical finding of pigmented nodules at pathological investigation might be lacking, although micronodules are present, as suggested by the group of Stratakis [13, 24]. In this subgroup of very young pediatric cases of PPNAD, Cushing’s syndrome might occur between birth and the age of 5 years. The main reason to differentiate this group of PPNAD or PPNAD-like patients is the lower rate of germline-inactivating mutations. In the cohort of patients studied by Bossis and Stratakis [24], germline-inactivating PRKAR1A mutations were present in 2 out of 10 patients. In our cohort of 25 patients with isolated PPNAD, the mutation rate of PRKAR1A is 65%. This rate is lower than in our cohort of patients with CNC (80%) who present mainly with PPNAD. Interestingly, in the subgroup of patients with isolated PPNAD, in whom Cushing’s syndrome was diagnosed before the age of 5 years, we have not found any germline PRKAR1A mutation [25, 26].

CNC1 Gene and Sporadic Adrenocortical Tumors

In sporadic adrenocortical tumors somatic PRKAR1A mutations have been found in secretory adrenal adenomas. The adrenal adenomas harboring somatic PRKAR1A mutations present with clinical, hormonal, and pathological features quite similar to PPNAD [21]. These latter adenomas are small tumors responsible for Cushing’s syndrome and present a paradoxical rise of cortisol after dexamethasone treatment. Allelic losses (LOH) at the PRKAR1A locus (17q22-24) have also been observed in sporadic adrenocortical tumors. In adrenocortical adenomas these LOH seem quite restricted to the PRKAR1A locus, suggesting that this tumor suppressor gene might be involved. By contrast, in adrenocortical cancers LOH seems to affect a large part of 17q, and PRKAR1A alteration might play a minor (or no) role in the growth of these tumors.

Unsolved Questions in the Genetics of CNC and PPNAD

The putative CNC2 gene located at the 2p16 locus remains to be determined [8, 18]. However, somatic alterations of the 2p16 region have been reported in CNC tumors, even in patients with a mutation of the CNC1 gene (i.e., PRKAR1A located on 17q22-24). These alterations are usually gene amplifications, suggesting a potential oncogene at 2p16 [22]. In sporadic adrenocortical tumors, 2p16 amplification has been also reported [22, 23]. Considering the genetics of isolated PPNAD, it should be mentioned that a subgroup of very young pediatric patients might be different from older patients related to CNC. In these patients, the classical finding of pigmented nodules at pathological investigation might be lacking, although micronodules are present, as suggested by the group of Stratakis [13, 24]. In this subgroup of very young pediatric cases of PPNAD, Cushing’s syndrome might occur between birth and the age of 5 years. The main reason to differentiate this group of PPNAD or PPNAD-like patients is the lower rate of germline-inactivating mutations. In the cohort of patients studied by Bossis and Stratakis [24], germline-inactivating PRKAR1A mutations were present in 2 out of 10 patients. In our cohort of 25 patients with isolated PPNAD, the mutation rate of PRKAR1A is 65%. This rate is lower than in our cohort of patients with CNC (80%) who present mainly with PPNAD. Interestingly, in the subgroup of patients with isolated PPNAD, in whom Cushing’s syndrome was diagnosed before the age of 5 years, we have not found any germline PRKAR1A mutation [25, 26].

PRKAR1A, Protein Kinase A (PKA), and the cAMP Signaling Pathway

PKA and the cAMP Signaling Pathway

The cAMP signaling pathway is one of the major transduction pathways that allow extracellular signals to be transmitted into the cell (fig. 3). The PKA is a central component of this pathway. PKA is a tetramer made by two regulatory subunits and two catalytic subunits. Four genes encode the regulatory subunits: PRKAR1A and PRKAR1B and PRKAR2A and PRKAR2B. The CNC gene, PRKAR1A, is ubiquitously expressed. According to results of initial experiments using elution in Sepharose gel-denaturing anion exchange chromatography, there are two types of PKA activity: PKA-I and PKA-II. It is usually accepted that the regulatory subunits present in the PKA-I activity fractions contain mainly PRKAR1A and PRKAR1B. Three genes encode the catalytic subunits (Cα, Cβ, and Cγ). Binding of cAMP to its two binding sites on the regulatory subunits leads to dissociation of the catalytic subunits from the regulatory ones, resulting in stimulation of the PKA catalytic activity (fig. 4). Activated PKA can phosphorylate on serine and threonine residues numerous proteins located on the membrane, in the cytoplasm, or, after nuclear entry of the catalytic subunit, in the nucleus. One of the most extensively studied nuclear targets of PKA is the transcription factor CREB (cAMP response element binding protein) that stimulates transcription after PKA phosphorylation [27]. The PKA activity is regulated by cellular trafficking. The A kinase anchoring proteins play a central role in this regulation.

Consequences of PRKAR1A Mutations in CNC and PPNAD

The consequences of PRKAR1A inactivation are currently investigated by several laboratories. Complete inactivation by homologous recombination in animal models is lethal during embryonic life [28]. Mesoderm and heart tube development alterations are observed in the mutant embryo. In these mice an increased basal PKA activity is observed. In heterozygous mice with PRKAR1A inactivation, it seems that the PKA activity is unaltered [20]. By contrast, in a transgenic mouse model expressing a PRKAR1A antisense construct leading to a 60% decrease of PRKAR1A mRNA and protein, the type II PKA activity is increased [29]. In this last model a marked increase of the type II/type I PKA activity is, therefore, observed. The PRKAR1A antisense expressing mice develop adrenocortical alterations that share some similarities...
with PPNAD, but with some differences. In the adrenocortical tissue of these mice, pigmentation alone seems not to be different from that of controls, but cortical hyperplasia is observed as well as congestion and X zone vacuolization [30]. Interestingly, obesity and increased corticosterone levels, both basal and after dexamethasone administration, are observed in these transgenic animals. Adrenocortical tumors from patients with PPNAD exhibit an increased PKA activity in response to cAMP [9] and also an increased type II/type I PKA activity ratio. Similarly, transient transfection of a PRKAR1A mutant that gives rise to a truncated protein is able to stimulate at the nuclear level the cAMP pathway [19]. In sporadic adrenocortical secreting adrenal adenomas that bear PRKAR1A-inactivating mutation or 17q22-24 LOH, an increased PKA activity in response to cAMP is also observed [21]. Despite all these results suggesting alterations of the distal part of the cAMP pathway from PKA to the nucleus after PRKAR1A inactivation, the mechanisms of tumor growth in PPNAD and CNC remain to be determined. It is possible that PRKAR1A inactivation exerts some effects on other signaling pathways more frequently involved in tumorigenesis. For instance, ERK2 activation has been observed in lymphocytes from patients with CNC and PRKAR1A germline mutation [31]. The same alterations of the mitogen-activated protein kinase pathway have been observed in cell lines established from patients with germline PRKAR1A-inactivating mutation.

Conclusions

The study of the genetics of a rare disease such as CNC allows a better understanding of adrenal Cushing’s syndrome and PPNAD, offering also new diagnostic molecular tools. It gives new insights into the mechanisms of endocrine tumorigenesis and adrenal tumor pathophysiology. Interestingly, various other molecular and cellular alterations of the cAMP signaling pathway have been observed in Cushing’s syndrome before the identification of the CNC1 gene. The PRKAR1A mutation (as shown in figure 5) is just another example of an alteration of this pathway, but interestingly it is so far the most distal component of the cAMP pathway presenting a molecular defect in endocrine tumors.

Acknowledgments

This work was supported in part by the Ligue National Contre le Cancer (Grant 04-7571) and the GIS-INSERM Institut des Maladies Rares for the Carney Complex Network.
References


Carney Complex and Cushing’s Syndrome

Horn Res 2005;64:132–139

139